Related Experiment Video
Updated: Jul 4, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Targeted Therapy for Prostate Cancer by Prostate-Specific Membrane Antigen-Targeted Small-Molecule Drug Conjugates
1Department of Synthetic Organic Chemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University.
Abstract:
In the aging global population, prostate cancer is a worldwide health problem because the incidence rate of this disease increases at advanced ages. Although early-stage prostate cancer can be treated by total prostatectomy, the surgery causes side effects, such as incontinence and dysuria, that lower QOL. Once the disease progresses to metastatic castration-resistant prostate cancer (mCRPC), there are no effective chemotherapeutic agents without systematic side effects. Therefore, targeted therapies for mCPRC are urgently needed. Traditional antibody-drug conjugate treatments for prostate cancer have been tested in clinical trials and several side effects have been observed. Meanwhile, small-molecule drug conjugates (SMDCs) have certain advantages over antibody drug conjugates in terms of non-immunogenicity, reproducibility, and permeability. In this review, prostate-specific membrane antigen-targeted SMDCs for treating prostate cancer are summarized.
Insights
Prostate cancer is a growing global health issue. This review focuses on prostate-specific membrane antigen-targeted small-molecule drug conjugates as a promising therapy for metastatic castration-resistant prostate cancer.
Area of Science:
- Oncology
- Drug Development
Background:
- Prostate cancer incidence rises with age, posing a global health challenge.
- Current treatments for metastatic castration-resistant prostate cancer (mCRPC) lack efficacy and cause significant side effects.
- Surgical options for early-stage prostate cancer lead to reduced quality of life due to side effects like incontinence.
Approach:
- This review summarizes prostate-specific membrane antigen (PSMA)-targeted small-molecule drug conjugates (SMDCs) for prostate cancer treatment.
- SMDCs offer advantages over antibody-drug conjugates, including reduced immunogenicity and improved permeability.
- The focus is on novel targeted therapies for advanced prostate cancer stages.
Key Points:
- PSMA-targeted SMDCs represent a novel therapeutic strategy for prostate cancer.
- SMDCs demonstrate potential for improved efficacy and reduced systemic toxicity compared to traditional therapies.
- The review highlights the advantages of SMDCs in overcoming limitations of existing treatments.
Conclusions:
- Targeted therapies are crucial for managing advanced prostate cancer.
- PSMA-targeted SMDCs show significant promise as an effective treatment modality for mCRPC.
- Further research and clinical trials are warranted to fully establish the role of SMDCs in prostate cancer care.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...